Chemomab Therapeutics

Pharmaceutical Manufacturing • Tel Aviv, Tel-Aviv District, Israel • 11-20 Employees

Company overview

Headquarters	Kiryat Atidim, Building 7, Tel Aviv, 6158002, IL
Phone number	+9726158002
Website	chemomab.com
NAICS	3254
SIC	283
Keywords	Rare Diseases, Fibrosis, Monoclonal Antibodies, Scleroderma, Primary Sclerosisng Cholangitis
Founded	2011
Employees	11-20
Socials

Key Contacts at Chemomab Therapeutics

Adi Mor

Ceo & Cso

Jill Thompson Quigley

Member Of The Board Of Directors

Chris Cirillo

Senior Director Clinical Operations

Chemomab Therapeutics Email Formats

Chemomab Therapeutics uses 4 email formats. The most common is {first initial}.{last name} (e.g., j.doe@chemomab.com), used 50% of the time.

Format	Example	Percentage
{first initial}.{last name}	j.doe@chemomab.com	66.7%
{first name}	john@chemomab.com	25%
{first name}.{last name}	john.doe@chemomab.com	8.3%

About Chemomab Therapeutics

Chemomab (Nasdaq: CMMB) is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed nebokitug (CM-101), a first-in-class dual activity monoclonal antibody that neutralizes CCL24 and has demonstrated disease-modifying potential. In clinical and preclinical studies, nebokitug has been shown to have a favorable safety profile and has been generally well-tolerated, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported positive results from four clinical trials of nebokitug in patients. Based on positive data from its Phase 2 SPRING trial in primary sclerosing cholangitis (PSC), the company is preparing for potential initiation of a nebokitug PSC Phase 3 trial. The FDA is aligned on the design of the Phase 3 study, which provides a clear and streamlined pathway to potential regulatory approval. Nebokitug has received FDA and EMA Orphan Drug status for PSC and systemic sclerosis and FDA Fast Track designation for PSC. Chemomab’s nebokitug systemic sclerosis program is Phase 2-ready and has an open U.S. IND.

Chemomab Therapeutics revenue & valuation

Annual revenue	$1,625,545
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues	$5,300,000
Total funding	No funding

Employees by Management Level

Total employees: 11-20

Seniority

Employees

C-Suite

Director

Vice President

Employees by Department

Chemomab Therapeutics has 4 employees across 4 departments.

Departments

Number of employees

Funding Data

Chemomab Therapeutics has never raised funding before.

Chemomab Therapeutics Tech Stack

Discover the technologies and tools that power Chemomab Therapeutics's digital infrastructure, from frameworks to analytics platforms.

Cloudflare

CDN

Microsoft Word

Editors

Linkedin Ads

Advertising

Google Tag Manager

Tag managers

Cookiebot

Cookie compliance

HSTS

Security

Open Graph

Miscellaneous

Linkedin Insight Tag

Analytics

Cookie Control

Cookie compliance

Google Analytics

Analytics

Netlify

CDN

MobX

JavaScript libraries

Frequently asked questions

Chemomab Therapeutics is located in Tel Aviv, Tel-Aviv District, IL.

You can reach Chemomab Therapeutics at +9726158002.

Chemomab Therapeutics was founded in 2011, making it 15 years old. The company has established itself as a significant player in its industry over this time.

Chemomab Therapeutics has approximately 11-20 employees. The company continues to grow its workforce to support its business operations and expansion.